Organo (6368) Q1 2026 earnings summary

Executive summary

• Orders received rose 13.0% year-over-year to ¥59,584 million, with net sales up 20.5% to ¥38,110 million for the quarter ended June 30, 2025.

• Operating profit surged 73.8% to ¥6,953 million, ordinary profit increased 48.1% to ¥6,471 million, and profit attributable to owners of parent grew 36.1% to ¥3,642 million year-over-year.

• The order backlog as of June 30, 2025, was ¥122,711 million, down 11.9% from the prior year.

Financial highlights

• Net sales: ¥38,110 million (up 20.5% year-over-year).

• Operating profit: ¥6,953 million (up 73.8% year-over-year).

• Ordinary profit: ¥6,471 million (up 48.1% year-over-year).

• Profit attributable to owners of parent: ¥3,642 million (up 36.1% year-over-year).

• Basic earnings per share: ¥79.25 (up from ¥58.25 year-over-year).

• Comprehensive income: ¥2,530 million (down 23.6% year-over-year).

Outlook and guidance

• Six-month forecast: Net sales ¥82,000 million, operating profit ¥14,800 million, profit attributable to owners of parent ¥9,700 million, basic EPS ¥211.03.

• Full-year forecast: Net sales ¥175,000 million, operating profit ¥34,000 million, profit attributable to owners of parent ¥26,100 million, basic EPS ¥567.81.

• Profits for both the first half and full year are expected to exceed initial forecasts due to cost reductions and improved profitability.